Chapter 25.6
Post-Transplantation Management and Complications
Faouzi Saliba,
Didier Samuel,
Faouzi Saliba
Search for more papers by this authorDidier Samuel
Search for more papers by this authorFaouzi Saliba,
Didier Samuel,
Faouzi Saliba
Search for more papers by this authorDidier Samuel
Search for more papers by this authorBook Editor(s):Juan Rodés MD,
Jean-Pierre Benhamou MD,
Andres T. Blei MD,
Jürg Reichen MD,
Mario Rizzetto MD,
Juan Rodés MD
Director General, Hospital Clinic; Professor of Medicine, University of Barcelona, Barcelona, Spain
Search for more papers by this authorJean-Pierre Benhamou MD
Professor of Hepatology, Université Denis Diderot Paris 7, Assistance Publique — Hôpitaux de Paris and Inserm U773, Service d'Hépatologie, Hôpital Beaujon, Clichy, France
Search for more papers by this authorAndres T. Blei MD
Professor of Medicine and Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorJürg Reichen MD
Professor of Medicine, University of Bern; Chief of Hepatology, University Hospital, Bern, Switzerland
Search for more papers by this authorMario Rizzetto MD
Professor of Gastroenterology, University of Turin, Turin, Italy
Search for more papers by this authorFirst published: 18 June 2007
References
- Adam R, McMaster P, O'Grady, JG et al; European Liver Transplant Association (2003) Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 9 (12), 1231.
- Seaberg EC, Belle SH, Beringer KC et al. (1999) Liver transplantation in the United States from 1987–1998: updated results from the Pitt UNOS liver transplant registry. In: JM Cecka, PI Terasaki (eds) Clinical Transplants 1998. Los Angeles: UCLA Tissue Typing Laboratory, pp. 17–37.
- Ciccarelli O, Kaczmarek B, Roggen F et al. (2005) Long-term medical complications and quality of life in adult recipients surviving 10 years or more after liver transplantation. Acta Gastroenterol Belg 68 (3), 323–330.
- Saliba F, Gugenheim J, Samuel D et al. (1987) Orthotopic liver transplantation in humans: monitoring by serial graft biopsies. Transplant Proc 19, 2454–2456.
- Sebagh M, Samuel D (2004) Place of the liver biopsy in liver transplantation. J Hepatol 41 (6), 897–901.
- Therapondos G, Hayes PC (2002) Is this the end for protocol early posttransplant liver biopsies' Liver Transpl 8 (12), 1154–1155.
- Lang M, Neumann UP, Muller AR et al. (1999) Complications of percutaneous liver biopsy in patients after liver transplantation. Z Gastroenterol 37 (3), 205–208.
-
Dobbels F,
Vanhaecke J,
Desmyttere A et al.
(2005)
Prevalence and correlates of self-reported pretransplant nonadherence with medication in heart, liver, and lung transplant candidates.
Transplantation
79
(11),
1588–1595.
10.1097/01.TP.0000158430.06507.87 Google Scholar
- Shemesh E, Shneider BL, Savitzky JK et al. (2004) Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics 113 (4), 825–832.
- Seyam MS, Gunson BK, Neuberger JM (2004) Late mortality in orthotopic liver transplant recipients who survive more than 5 years. Single center experience. Hepatology 40, 262A.
- Rabkin JM, de La Melena V, Orloff, SL et al. (2001) Late mortality after orthotopic liver transplantation. Am J Surg 181 (5), 475–479.
- Jain A, Reyes J, Kashyap R et al. (1999) What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 230 (3), 441–448.
- Everhart JE, Lombardero M, Lake JR et al. (1998) Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg, 4 (4) 285–296.
- Neal DA, Tom BD, Gimson AE et al. (2001) Hyperuricemia, gout, and renal function after liver transplantation. Transplantation 27, 72 (10), 1689–1691.
- Richards J, Gunson B, Johnson J et al. (2005) Weight gain and obesity after liver transplantation. Transpl Int 18 (4), 461–466.
- Romero M, Parera A, Salcedo M et al. (1999) Cardiovascular risk factors and late cardiovascular disease in liver transplantation. Transplant Proc 31 (6), 2364–2365.
- Neal DA, Tom BD, Luan J et al. (2004) Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 77 (1), 93–99.
- Johnston SD, Morris JK, Cramb R et al. (2002) Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73 (6), 901–906.
- Munoz SJ, Elgenaidi H (2005) Cardiovascular risk factors after liver transplantation. Liver Transpl 11 (Suppl. 2), S52–56.
- Canzanello VJ, Schwartz L, Taler SJ et al. (1997) Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg, 3 (1) 1–9.
- Textor SC, Taler SJ, Canzanello VJ et al. (2000) Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 6 (5), 521–530.
- Neal DA, Brown MJ, Wilkinson IB et al. (2005) Mechanisms of hypertension after liver transplantation. Transplantation 79 (8), 935–940.
- Galioto A, Angeli P, Guarda S et al. (2005) Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial. Transplant Proc 37 (2), 1245–1247.
- Heisel O, Heisel R, Balshaw R et al. (2004) New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 4 (4), 583–595.
- Levy G, Villamil F, Samuel D et al.;LIS2T Study Group (2004) Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 77 (11), 1632–1638.
- Bigam DL, Pennington JJ, Carpentier A et al. (2000) Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 32 (1), 87–90.
- Khalili M, Lim JW, Bass N et al. (2004) New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 10 (3), 349–355.
- AlDosary AA, Ramji AS, Elliott, TG et al. (2002) Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl 8 (4), 356–361.
- Baid S, Cosimi AB, Farrell ML et al. (2001) Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 72 (6), 1066–1072.
- John PR, Thuluvath PJ (2002) Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 8 (8), 708–713.
- Fellstrom B (2001) Risk factors for and management of posttransplantation cardiovascular disease. Bio Drugs 15 (4), 261–278.
- Gisbert C, Prieto M, Berenguer M et al. (1997) Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 3 (4), 416–422.
- Hulzebos CV, Bijleveld CM, Stellaard F et al. (2004) Cyclosporine A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation. Liver Transpl 10 (7), 872–880.
- Charco R, Cantarell C, Vargas V et al. (1999) Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. Liver Transpl Surg 5 (3), 204–208.
- Imagawa DK, Dawson S 3rd, Holt, CD et al. (1996) Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation 62 (7), 934–942.
- Gonwa TA, Mai ML, Melton LB et al. (2001) Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation 71, 1424.
- Gonwa TA, Mai ML, Melton LB et al. (2001) End stage renal disease following orthotopic liver transplantation utilizing calcineurin based immunotherapy: risk of development and treatment. Transplantation 72, 1934.
- Kendrick EA, McVicar JP, Kowdley KV et al. (1997) Renal disease in hepatitis C-positive liver transplant recipients. Transplantation 63 (9), 1287–1293.
- Gayowski T, Singh N, Keyes L et al. (2000) Late-onset renal failure after liver transplantation: role of posttransplant alcohol use. Transplantation 69 (3), 383–388.
- Paramesh AS, Roayaie S, Doan Y et al. (2004) Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 18 (1), 94–99.
- Platz KP, Mueller AR, Blumhardt G et al. (1994) Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 58 (2), 170–178.
- Jain A, Vekatramanan R, Eghtesad B et al. (2005) Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 80 (6), 859–864.
- Scheifele C, Reichart PA, Hippler-Benscheidt, M et al. (2005) Incidence of oral, pharyngeal, and laryngeal squamous cell carcinomas among 1515 patients after liver transplantation. Oral Oncol4 1 (7), 670–676.
- Jimenez C, Marques E, Manrique A et al. (2005) Incidence and risk factors of development of lung tumors after liver transplantation. Transplant Proc 37 (9), 3970–3972.
- Jain AB, Yee LD, Nalesnik MA et al. (1998) Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 66 (9), 1193–2000.
- Graziadei IW, Nachbaur K, Koenigsrainer A et al. (2003) Incidence and prognosis of de-novo malignancies after liver transplantation. Hepatology 38, 256A.
- Jain A, Nalesnik M, Reyes J et al. (2002) Posttransplant lymphoprolif-erative disorders in liver transplantation: a 20-year experience. Ann Surg 236 (4), 429–436.
- Jain AB, Marcos A, Pokharna R et al. (2005) Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 80 (12), 1692–1698.
- Oertel SH, Verschuuren E, Reinke P et al. (2005) Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder. Am J Transplant 5 (12), 2901–2906.
- Monegal A, Navasa M, Guanabens N et al. (2001) Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12 (6), 484–492.
-
Charlton M,
Narayanan Menon KV
(2005)
Late complications of liver transplantation and recurrence of disease. In:
Busuttil and
Klintmalm (eds)
Transplantation of the Liver,
2nd edn.
Philadelphia:
Elsevier,
pp. 995–1017.
10.1016/B978-0-7216-0118-2.50070-7 Google Scholar
- Wiesner RH, Shorr JS, Steffen BJ et al. (2005) Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 11 (7), 750–759.
- Moreno Planas JM, Cuervas-Mons Martinez, V, Rubio Gonzalez, E et al. (2004) Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 4 (10), 1650–1655.
- Sanchez EQ, Martin AP, Ikegami T et al. (2005) Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 37 (10), 4416–4423.
- Wiesner RH, Demetris AJ, Belle SH et al. (1998) Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28 (3), 638–645.
- Mor E, Gonwa TA, Husberg BS et al. (1992) Late-onset acute rejection in orthotopic liver transplantation — associated risk factors and outcome. Transplantation 54 (5), 821–824.
- Wiesner RH, Batts KP, Krom RA (1999) Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection. Liver Transpl Surg 5 (5), 388–400.
- Pappo O, Ramos H, Starzl TE et al. (1995) Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 19 (2), 192–206.
- Hubscher SG (2001) Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl 7 (4), 285–291.
- Jain AB, Reyes J, Marcos A et al. (2003) Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation, 76 (5) 827–832.
